Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Recent News

Priority Review Granted by FDA to Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
Early Research Findings on Novel Bispecific Monoclonal Antibody in Resistant Myeloma
FDA Brief: Cemiplimab-rwlc Accepted for Review in First-Line Combination Therapy for Advanced Lung Cancer
Time-Limited Venetoclax-Based Combination Therapies for CLL
Final Survival Analysis of Immotion151: Atezolizumab Plus Bevacizumab in Metastatic Kidney Cancer
T-DXd Versus T-DM1 in Metastatic Breast Cancer: Subgroup Analyses From DESTINY-Breast03
Phase III GMMG-HD7 Trial: Isatuximab-Based Therapy for Newly Diagnosed Myeloma
Use of Cemiplimab in Elderly, Frail Patients With Cutaneous Squamous Cell Carcinoma
How Does Pembrolizumab Impact the Tumor Microenvironment of Triple-Negative Breast Cancer?
Activating T Cells With Talquetamab to Treat Multiple Myeloma
Extended Follow-up With Daratumumab-Based Regimen in Newly Diagnosed Myeloma
Anti-TIGIT Monoclonal Antibody Plus Pembrolizumab Focus of Phase II Study in NSCLC
First-in-Class Targeted Cellular Therapy Under Study in Resistant Multiple Myeloma
ASH 2021: Predictive Potential of Immunosuppressive Phenotypes on Outcomes in AML
ASH 2021: Novel BCMA-Targeting Bispecific Antibody Under Study in Resistant Myeloma
Biomarker-Directed Analysis of First-Line Pembrolizumab-Based Therapies in NSCLC
ASH 2021: Bispecific Antibody Teclistamab in Early-Phase Myeloma Study
ASH 2021: Updated Phase III FLAIR Results of Ibrutinib Plus Rituximab in Previously Untreated CLL
ASH 2021: Novel Immunocytokine Under Study in Resistant Multiple Myeloma
Transcriptome Sequencing and T-Cell Receptor Spatial Mapping in Renal Cell Carcinoma
Tumor Biopsy Analysis of Anticancer Vaccine–Treated Patients With Advanced NSCLC
SABCS 2021: KEYNOTE-355 Final Results of Pembrolizumab Plus Chemotherapy in Triple-Negative Breast Cancer
ASH 2021: Combination Umbralisib and Ublituximab With Ibrutinib in CLL
ASH 2021: Combination Iberdomide and Dexamethasone for Resistant Multiple Myeloma
Chemoradiation Plus Pembrolizumab for Locally Advanced NSCLC
SITC 2021: Anti-CD47 Immunotherapy Under Study for Reducing Breast Cancer Brain Metastasis
SITC 2021: How Genetic Reprogramming of Merkel Cell Carcinoma May Impact MHC-I Expression and Immune Response
SITC 2021: Early-Phase Study Results of LN-145 Monotherapy in NSCLC
Ipilimumab Plus Nivolumab Therapy for Renal Cell Carcinoma With Brain Metastasis
Pediatric KMT2A-Rearranged AML: CD33-Targeted Agent Focus of Phase III Trial
Combination Obinutuzumab Treatment and MRD Kinetics in CLL: Insights From CLL14 Study
SITC 2021: Preclinical Study of Microbial Immunotherapy in Bladder Cancer
SITC 2021: Phase II Study Results of Retifanlimab in Advanced Merkel Cell Carcinoma
SITC 2021: Immunomodulatory Effects of Neoadjuvant Nivolumab and Chemotherapy in NSCLC
Copyright © 2022 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.